नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 150 mg

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 50 mg

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

orifarm as - bikalutamid - tablett, filmdrasjert - 50 mg

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

orifarm as - bikalutamid - tablett, filmdrasjert - 150 mg

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

orifarm as - bikalutamid - tablett, filmdrasjert - 150 mg

यूरोपीय संघ - नॉर्वेजियाई - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - bryst neoplasms - endokrin terapi, anti-østrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i pre - eller perimenopausal women, kombinert behandling med palbociclib bør kombineres med en luteiniserende hormon-frigjørende hormon (lhrh) agonist.

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

n.v. organon - kloosterstraat - mometasonfuroatmonohydrat - nesespray, suspensjon - 50 mikrog/ dose

नॉर्वे - नॉर्वेजियाई - Ecolab

ecolab deutschland gmbh -

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

farmagon - mometasonfuroat - nesespray, suspensjon - 50 mikrog/ dose

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

farmagon - mometasonfuroat - nesespray, suspensjon - 50 mikrog/ dose